Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells

Biomarker Insights

Volumn 3, Issue , 2008, Pages

  Brust, Anja Kristina ^a   Ulbrich, Holger K ^a   Seigel, Gail M ^b   Pfeiffer, Norbert ^a   Grus, Franz H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

apoptosis; biomarker neuroprotection of apoptotic neuroretinal cells; cyclooxygenase; neuroprotection; PGE2; retinal ganglion cells; Seldi Maldi

Indexed keywords

EID: 84888642164     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S692     Document Type: Article

References (45)

1. Agar A., Shaojuan L., Agarwal N., Coroneo M.T., and Hill M.A. 2006. Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res., 1086: 191–200.
2. Bagetta G., Corasaniti M.T., Paoletti A.M., Berliocchi L., Nistico R., Giammarioli A.M., Malorni W., and Finazzi-Agro A. 1998. HIV-1 gp 120-induced apoptosis in the rat neocortex involves enhanced expression of cyclooxygenase type 2 (COX-2). Biochem. Biophys. Res. Commun., 244: 819–24.
3. Bazan N.G. 1998. The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Prog. Brain Res., 118: 281–91.
4. Bazan N.G. 2001. COX-2 as a multifunctional neuronal modulator. Nat. Med., 7: 414–5.
5. Cazevieille C., Muller A., Meynier F., Dutrait N., and Bonne C. 1994. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem. Int., 24: 395–408.
6. Choi D.W. 1992. Excitotoxic cell death. J. Neurobiol., 23: 1261–76.
7. Coleman A.L. 1999. Glaucoma. Lancet, 354: 1803–10.
8. Choi D.W. 1992. Excitotoxic cell death. J. Neurobiol., 23: 1261–76.
9. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., and Van de Putte L.B.A. 1998. Cyclooxygenase in biology and disease. FASEB. J., 12: 1063–73.
10. Grosser T., Fries S., and FitzGerald G.A. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest., 116: 4–15.
11. Grus F.H., Podust V.N., Bruns K., Lackner K., Fu S., Dalmasso E.A., Wirthlin A., and Pfeiffer N. 2005. SELDI-TOF-MS ProteinChip array Profiling of tears from patients with dry eye. Invest. Ophthalmol. Visual. Sci., 46: 863–76.
12. Grus F.H., Joachim S.C., Bruns K., Lackner K.J., Pfeiffer N., and Wax M.B. 2006. Serum autoantibodies to α-Fodrin are present in glaucoma patients from Germany and the United States. Invest. Ophthalmol. Visual. Sci., 47: 968–76.
13. Hare W.A., WoldeMussie E., Weinreb R.N., Lai R.K., Ton H., and Ruiz G. 2004. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey. I. Functional measures. Invest Ophthalmol. Vis. Sci., 45: 2625–39. Erratum in Invest Ophthalmol. Vis. Sci., 2004; 45: 2878.
14. Hewett S., Uliasz T.F., Vidwans A.S., and Hewett J.A. 2000. Cyclooxygenase-2 contributes to N-methyl-d-aspartate mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther., 293: 417–25.
15. Hickey R.W., Zhu R.L., Alexander H.L., Jin K.L., Stetler R.A., Chen J., Kochanek P.M., and Graham S.H. 2000. 10 kD mitochondrial matrix heat shock protein mRNA is induced following global brain ischemia in the rat. Brain Res. Mol. Brain Res., 79: 169–73.
16. Hurley S.D., Olschowka J.A., and O'Banion M.K. 2002. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J. Neurotrauma., 19: 1–15.
17. Hoyng P.F., and Kitazawa Y. 2002. Medical treatment of normal tension glaucoma. Surv. Ophthalmol., 47: 116–24.
18. Iadecola C., Niwa K., and Nogawa S. 2001. Reduced susceptibility to ischemic brain injury and N-methyl-daspartate-mediated neurotoxicity in cyclooxygenase-2 deficient mice. Proc. Natl. Acad. Sci., 98: 1294–9.
19. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., and Miller J.P. 2002. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol., 120: 701–13.
20. Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., Kunz A., Cho S., Orio M., and Iadecola C. 2006. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med., 12: 225–9.
21. Kim S.H., Fountoulakis M., Cairns N.J., and Lubec G. 2002. Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem. Biophys. Res. Commun., 296: 970–5.
22. Kosnosky W., Tripathi B.J., and Tripathi T.C. 1995. An in vitro system for studying pressure effects on growth, morphology and biochemical aspects of trabecular meshwork cells. Invest. Ophthalmol. Visual. Sci., 36: 8731.
23. Li C.S. and Black W.C., Brideau C., Chan C.C., Charleson S., and Cromlish W.A. 1999. A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett., 9: 3181–6.
24. Li Z., Jansen M., Pierre S.R., and Figueiredo-Pereira M.E. 2003. Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation. Int. J. Biochem. Cell Biol., 35: 547–52.
25. Lowe J., Mayer J., Landon M., and Layfield R. 2001. Ubiquitin and the molecular pathology of neurodegenerative diseases. Adv. Exp. Med. Biol., 487: 169–86.
26. Maihofner C., Schlotzer-Schrehardt U., Guhring H., Zeilhofer H.U., Naumann G.O., Pahl A., Mardin C., Tamm E.R., and Brune K. 2001. Expression of cyclooxygenase-1 and –2 in normal and glaucomatous human eyes. Invest Ophthalmol. Vis. Sci., 42: 2616–24.
27. McGeer P.L., Schulzer M., and McGeer E.G. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology, 47: 425–32.
28. Miettinen S., Fusco F.R., Yrjänheikki J., Keinänen R., Hirvonen T., and Roivainen R. 1997. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-d-aspartic acid-receptors and phospholipase A2. Proc. Natl. Acad. Sci., 94: 6500–5.
29. Nakayama M., Uchimura K., and Zhu R.L. 1998. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci., 95: 10954–59.
30. Niederberger E., Manderscheid C., Grösch S., Schmidt H., Ehnert, and Geisslinger G. 2004. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem. Pharmacol., 68: 341–50.
31. Osborne N.N., Melena J., Chidlow G., and Wood J.P. 2001. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br. J. Ophthalmol., 85: 1252–59.
32. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., and Docter S. 1997. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem., 40: 1347–65.
33. Quigley H.A. 1996. Number of people with glaucoma worldwide. Br. J. Ophthalmol., 80: 389–93.
34. Smith W.L., Garavito R.M., and DeWitt D.L. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and –2. J. Biol. Chem., 271: 33157–60.
35. Seigel G.M., Mutchler A.L., and Imperato E.L. 1996. Expression of glial markers in a retinal precursor cell line. Mol. Vis., 2: 2.
36. Seigel G.M. 1996. Establishment of an E1A-immortalizedretinal cell culture. In Vitro Cell Dev. Biol. Anim., 32: 66–8.
37. Seigel G.M., Chiu L., and Paxhia A. 2000. Inhibition of neuroretinal cell death by insulin-like growth factor-1and its analogs. Molecular Vision, 6: 157–63.
38. Strauss K.I., and Marini A.M. 2002. Cyclooxygenas-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death. J. Neurotrauma., 19: 627–38.
39. Tacconelli S., Capone M.L., Sciulli M.G., Ricciotti E., and Patrignani P. 2002. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr. Med. Res. Opin., 18: 503–11.
40. Thérien M., Gauthier J.Y., Leblanc Y., Léger S., Perrier H., and Prasit P. 2001. Synthesis of Rofecoxib, (MK 0966, Vioxx® 4-(4′-Methylsulfonylphenyl)-3-Phenyl-2(5H)-Furanone), a Selective and Orally Active Inhibitor of Cyclooxygenase-2. Synthesis, 12: 1778–9.
41. Vane J.R., Bakhle Y.S., and Botting R.M. 1998. Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol., 38: 97–120.
42. Wax M.B., Tezel G., Kobayashi S., and Hernandez M.R. 2000. Responses of different cell lines from ocular tissues to elevated hydrostatic pressure. Br. J. Ophthalmol., 84: 423–8.
43. Wolde Mussie E., Yoles E., Schwartz M., Ruiz G., and Wheeler L.A. 2002. Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma, 11: 474–80.
44. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., and Worley P.F. 1993. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron, 11: 371–86.
45. Yucel Y.H., Gupta N., Zhang Q., Mizisin A.P., Kalichman M.W., and Weinreb R.N. 2006. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch. Ophthalmol., 124: 217–25.